Literature DB >> 11360201

p14ARF homozygous deletion or MDM2 overexpression in Burkitt lymphoma lines carrying wild type p53.

M S Lindström1, U Klangby, K G Wiman.   

Abstract

The hallmark of Burkitt lymphoma (BL) is a constitutively activated c-myc gene that drives tumor cell growth. A majority of BL-derived cell lines also carry mutant p53. In addition, the p16INK4a promoter is hypermethylated in most BL biopsies and BL cell lines, leading to silencing of this gene. Activation of c-myc and/or cell cycle dysregulation can induce ARF expression and p53-dependent apoptosis. We therefore investigated the p14ARF-MDM2-p53 pathway in BL cell lines. p14ARF was expressed and localized to nucleoli in all BL carrying mutant p53. Three out of seven BL carrying wt p53 had a homozygous deletion of the CDKN2A locus that encodes both p14ARF and p16INK4a. Three BL carrying wild type p53 retained the CDKN2A locus and overexpressed MDM2. DNA sequencing revealed a point mutation in CDKN2A exon 2 in one of these BL, Seraphine. However, this point mutation did not affect p14ARF's nucleolar localization or ability to induce p53. The Bmi-1 protein that negatively regulates the p14ARF promoter and co-operates with c-myc in tumorigenesis was expressed at low to moderate levels in all BL analysed. Our results indicate that inactivation of the ARF-MDM2-p53 pathway is an essential step during the development of Burkitt lymphoma, presumably as a mechanism to escape c-myc induced apoptosis.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11360201     DOI: 10.1038/sj.onc.1204303

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  26 in total

1.  Reactive oxygen signaling and MAPK activation distinguish Epstein-Barr Virus (EBV)-positive versus EBV-negative Burkitt's lymphoma.

Authors:  Francesca Cerimele; Traci Battle; Rebecca Lynch; David A Frank; Emma Murad; Cynthia Cohen; Nada Macaron; John Sixbey; Kenneth Smith; Randolph S Watnick; Aristidis Eliopoulos; Bahig Shehata; Jack L Arbiser
Journal:  Proc Natl Acad Sci U S A       Date:  2004-12-20       Impact factor: 11.205

2.  B-cell specific Moloney leukemia virus insert site 1 and peptidyl arginine deiminase IV positively regulate carcinogenesis and progression of esophageal squamous cell carcinoma.

Authors:  Wei Wang; Huai-Jun Ji; Ning-Bo Sun; Xiao-Tian Chang; Bing Xu; Yao Wang; Ming Cao; Qiang Zhu; Qi Zang; Zhong-Min Jiang
Journal:  Oncol Lett       Date:  2017-04-06       Impact factor: 2.967

3.  Proteomic analysis of mantle-cell lymphoma by protein microarray.

Authors:  Irene M Ghobrial; Daniel J McCormick; Scott H Kaufmann; Alexey A Leontovich; David A Loegering; Nga T Dai; Kelly L Krajnik; Mary J Stenson; Mona F Melhem; Anne J Novak; Stephen M Ansell; Thomas E Witzig
Journal:  Blood       Date:  2005-01-13       Impact factor: 22.113

4.  Essential role of phospholipase C gamma 2 in early B-cell development and Myc-mediated lymphomagenesis.

Authors:  Renren Wen; Yuhong Chen; Li Bai; Guoping Fu; James Schuman; Xuezhi Dai; Hu Zeng; Chunying Yang; Robert P Stephan; John L Cleveland; Demin Wang
Journal:  Mol Cell Biol       Date:  2006-10-09       Impact factor: 4.272

5.  Polycomb repressive complex 2 contributes to DNA double-strand break repair.

Authors:  Stuart Campbell; Ismail Hassan Ismail; Leah C Young; Guy G Poirier; Michael J Hendzel
Journal:  Cell Cycle       Date:  2013-07-29       Impact factor: 4.534

6.  Intensive expression of Bmi-1 is a new independent predictor of poor outcome in patients with ovarian carcinoma.

Authors:  Guo-Fen Yang; Wei-Peng He; Mu-Yan Cai; Li-Ru He; Jun-Hang Luo; Hai-Xia Deng; Xin-Yuan Guan; Mu-Sheng Zeng; Yi-Xin Zeng; Dan Xie
Journal:  BMC Cancer       Date:  2010-04-08       Impact factor: 4.430

7.  p53 status dictates responses of B lymphomas to monotherapy with proteasome inhibitors.

Authors:  Duonan Yu; Martin Carroll; Andrei Thomas-Tikhonenko
Journal:  Blood       Date:  2007-02-06       Impact factor: 22.113

8.  Selection against PUMA gene expression in Myc-driven B-cell lymphomagenesis.

Authors:  Sean P Garrison; John R Jeffers; Chunying Yang; Jonas A Nilsson; Mark A Hall; Jerold E Rehg; Wen Yue; Jian Yu; Lin Zhang; Mihaela Onciu; Jeffery T Sample; John L Cleveland; Gerard P Zambetti
Journal:  Mol Cell Biol       Date:  2008-06-23       Impact factor: 4.272

Review 9.  Mechanisms involved in Burkitt's tumor formation.

Authors:  M R Campanero
Journal:  Clin Transl Oncol       Date:  2008-05       Impact factor: 3.405

10.  Discovery, in vivo activity, and mechanism of action of a small-molecule p53 activator.

Authors:  Sonia Lain; Jonathan J Hollick; Johanna Campbell; Oliver D Staples; Maureen Higgins; Mustapha Aoubala; Anna McCarthy; Virginia Appleyard; Karen E Murray; Lee Baker; Alastair Thompson; Joanne Mathers; Stephen J Holland; Michael J R Stark; Georgia Pass; Julie Woods; David P Lane; Nicholas J Westwood
Journal:  Cancer Cell       Date:  2008-05       Impact factor: 31.743

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.